Form 4: Lilly Endowment Sells 134K+ Eli Lilly Shares in Planned Trade

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 134,393 shares of common stock on October 1, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co. (LLY), filed a Form 4 statement.
• The filing details the sale of 134,393 shares of Eli Lilly & Co. common stock on October 1, 2025.
• The sales were executed at weighted average prices ranging from $765.75 to $807.406 per share.
• Following these transactions, Lilly Endowment Inc. beneficially owns 95,357,800 shares of Eli Lilly & Co. common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• This Form 4 represents the first of two filings by Lilly Endowment Inc. on October 2, 2025, covering transactions #1 through #30 of a total of 55 transactions.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a large insider sale, but mitigated by the fact that it was executed under a pre-arranged 10b5-1 plan, suggesting it's not based on new, adverse information.

Positives

• The sales were conducted under a Rule 10b5-1(c) trading plan, indicating pre-scheduled transactions not based on new, non-public information, which can mitigate negative market interpretations of insider selling.

Negatives

• A significant reduction in direct beneficial ownership by a 10% owner, totaling 134,393 shares, could be perceived as a negative signal by some investors, despite being part of a pre-arranged plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "This is the first of two Forms 4 filed by the Reporting Person on same date, October 2, 2025, representing transactions #1 through #30 of 55 total transactions." (Paraphrased from Remarks section)

Industry Context

This filing reflects an ownership change by a significant institutional shareholder in Eli Lilly & Co., a major pharmaceutical company. Such transactions are common for large endowments and foundations managing diversified portfolios, often executed through pre-planned trading strategies.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., engaged in the sale of common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may observe a reduction in the beneficial ownership of a significant institutional investor, which could influence market sentiment, although the 10b5-1 plan context suggests a routine portfolio adjustment.

Next Steps

• Lilly Endowment Inc. is expected to file a second Form 4 on October 2, 2025, to report the remaining transactions (31-55) of the total 55 transactions.

Key Dates

Recommendation

The filing details a large insider sale by a 10% owner, Lilly Endowment Inc. However, the transactions were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new, material non-public information. While a large sale could be perceived negatively, the planned nature of the transaction suggests it's a portfolio management decision rather than a signal of deteriorating company fundamentals. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Eli Lilly & Co, LLY, Lilly Endowment Inc., Form 4, Insider Trading, Stock Sale, 10% Owner, Pharmaceuticals, SEC Filing, 10b5-1 Plan